We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Edenville | LSE:EDE | London | Ordinary Share | GB00B05MCJ34 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
01/12/2014 18:46 | have these gone belly up cant find any prices for them | metamick | |
28/6/2013 08:12 | Q&A : Edge Resources chief expects production to double over next year By Proactive Investors June 27 2013, 3:10pm 'A year from now we should easily be double our current production.'"A year from now we should easily be double our current production." Edge Resources, (LON:EDG CVE:EDE) a Canadian oil and gas company, recently announced a significant increase in its reserve and net present value. Brad Nichol, president and chief executive explains the significance and potential. | lucky_punter | |
30/3/2012 12:52 | Eden Research has revealed plans to float on AIM in a listing that will give it a market capitalisation of about £20m. | monet | |
24/2/2012 08:57 | Data Access and Royalty Agreement with Xeda International: | weyweyumfozo | |
22/2/2012 10:46 | Memorandum of Understanding with FMC Corporation: Appointment of Zeus Capital as advisor: | weyweyumfozo | |
06/1/2012 13:59 | Fantastic news more to come in next few weeks,move to AIM. Teva Animal Health, Inc. exercises option that provides exclusive license rights with Eden Exclusive license agreement for NAFTA region Culmination of two years product development and trial work USD 100,000 fee received with further milestones and royalties on product sales Eden Research plc, the agrochemical and encapsulation development company, is pleased to announce that, following extensive development and trials, Teva Animal Health, Inc. ("TAH") has formally decided to exercise its option and thereby enter into a licensing agreement with Eden. The licensing agreement gives TAH the exclusive rights to develop, manufacture and market products in the future for the treatment of common bacterial, fungal, and/or parasitic pathogens in the veterinary health space in the North American Free Trade Agreement ("NAFTA") region. In addition to the USD 100,000 licence fee received, the agreement provides for TAH to pay further milestone payments totalling USD 800,000, plus royalty payments once sales of the products begin. Clive Newitt, Managing Director of Eden, said, "We have been working closely with TAH since January 2010 to help develop products which meet their needs for treating various issues in veterinary health. I'm delighted that the result of this work is a formal, exclusive licensing agreement with a subsidiary of one of the largest pharmaceutical companies in the world. The fact that we have reached this commercial agreement with such a major, global company as Teva Animal Health Inc. underpins the efficacy and commercial potential of our products." The Directors of Eden are responsible for the contents of this announcement | monet | |
27/9/2011 18:24 | foolow eden through the michael walters site company moving in right direction worth joining just for eden news alone. | pranchalee | |
27/9/2011 13:03 | Yes ,I am and have been hoping for some news for a while especially as regards Europe and the red tape which seems to continue to delay approval of their 3AEY. I hope you're right that we should have some news soon. | pondinan | |
28/8/2011 15:30 | anyone still interested in this company next 3-6 months could be interesting | pranchalee | |
19/8/2011 11:09 | Interim Results: | weyweyumfozo | |
24/2/2011 14:16 | It's this one, Eden Research, posted on the MW free list by mistake: 08:40 23/02/2011 Eden granted 'nematodes' patent in Australia StockMarketWire.com - UK agrochemical development firm Eden Research has been granted its first 'nematodes' patent in Australia. The patent, which is for the use of Eden's platform encapsulation technology with terpenes as a nematicide, is also in an advanced state of registration in a number of other countries. The patented encapsulation system itself has already been granted in a number of territories. Nematodes are microscopic, soil-dwelling worms measuring approximately 0.1-5 mm in length. Nematode populations can cause considerable damage to a wide range of high-value vegetable crops and horticultural species. Eden has already licensed its nematicide product in South America to Stockton Agrimor AG and granted an option for the product to Certis Europe BV to enter into an exclusive licence for Europe, Asia, Africa, the Middle East and Oceania. MD Clive Newitt said, "The nematode market has been as high as $1.1bn worldwide but due to regulatory withdrawal of many previous products, such as Temik (aldicarb), there is a vacuum waiting to be filled by naturally derived, effective, cost competitive products such as Eden's. "The granting of this patent is important not only for the nematode licences that we have signed to date, but, also for reinforcing the value of the company's intellectual property." | monet | |
11/9/2010 09:56 | Nice mention in today's dailymail 'coal seams are popping up left, right & centre' | davethechef | |
17/5/2010 09:55 | March 29 Commenting today Simon Rollason, Executive Chairman, said; "I am delighted that this transaction has been concluded to the satisfaction of our shareholders and allows us to move the company forward. We have a highly prospective portfolio of projects in a very exciting part of Africa. Our priority targets in Tanzania are the Matiri North and South licenses where we hope to quickly identify and delineate economic coal and uranium resources. Our strategy going forward is to bring coal into production for a domestic Southern African market and we believe our location in the Government supported Mtwara Development Corridor places us in an ideal position to sell product within the region. Edenville shall also look to develop uranium exports to international nuclear utilities companies. Edenville will also continue evaluating other energy mineral properties. Our exploration season is scheduled to begin by the end of H1 2010 and we intend to efficiently recover data and return results to shareholders." The Company will actively manage geological exploration on the licences with planning and preparation for field-based activities being conducted in April and May, the rainy season in Tanzania. Geological prospecting is expected to commence in late Q2 of 2010. * so rainy season ending this month maybe they'll update on their plans for geological drilling end of the month? | andrbea | |
12/5/2010 13:11 | come on whats happening.... someone must know something... | ardluilord | |
12/5/2010 12:05 | lots of buying movement I hope | ardluilord | |
30/4/2010 08:29 | back to sleep for this share then..... | never_say_never | |
23/4/2010 11:11 | ...maybe just suspended 4 missing accounts submission deadline...thn again, possibly something more exciting?? | visa33 | |
23/4/2010 10:41 | hopefully will open with a rise | ardluilord | |
23/4/2010 08:20 | Yes , i have an interest in this share. Could it be that the suspension is due to then moving from Plus to Aim ? If anyone has any information or thoughts please post | 10km | |
16/4/2010 07:25 | Is any one interested in this share...An RNS released this morning... | never_say_never | |
14/4/2010 09:30 | power of buys this morning whats happening | ardluilord | |
09/4/2010 10:02 | AND YET MORE BUYS its getting like fun LOLO.... | ardluilord |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions